ADARx Pharmaceuticals (ADRX) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mineralys Therapeutics is the larger company by market cap ($2.01 billion vs $1.88 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | MLYS |
|---|---|---|
| Share price | $17.61 | $22.77 |
| Market cap | $1.88B | $2.01B |
| 1-day change | -0.37% | +1.74% |
| YTD return | — | -38.33% |
| 1-year return | — | -40.30% |
| EPS (TTM) | $-1.16 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-154.65M |
| 52-week high | $23.21 | $47.65 |
| 52-week low | $16.64 | $21.46 |
| Distance from 52-week high | -24.13% | -52.21% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +113.00% |
| Average volume | 1.25M | 1.04M |
| Shares outstanding | 106.80M | 88.41M |
| Employees | 100 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
ADRX vs MLYS FAQ
Which is bigger, ADARx Pharmaceuticals or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $2.01B compared with $1.88B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.